Arora, P.; Kempf, A.; Nehlmeier, I.; Schulz, S.R.; Jäck, H.-M.; Hoffmann, M.; Pöhlmann, S.
Entry Efficiency, Protease Dependence, and Antibody-Mediated Neutralization of SARS-CoV-2 Sublineages KP.3.1.1 and XEC. Vaccines 2025, 13, 385.
https://doi.org/10.3390/vaccines13040385
AMA Style
Arora P, Kempf A, Nehlmeier I, Schulz SR, Jäck H-M, Hoffmann M, Pöhlmann S.
Entry Efficiency, Protease Dependence, and Antibody-Mediated Neutralization of SARS-CoV-2 Sublineages KP.3.1.1 and XEC. Vaccines. 2025; 13(4):385.
https://doi.org/10.3390/vaccines13040385
Chicago/Turabian Style
Arora, Prerna, Amy Kempf, Inga Nehlmeier, Sebastian R. Schulz, Hans-Martin Jäck, Markus Hoffmann, and Stefan Pöhlmann.
2025. "Entry Efficiency, Protease Dependence, and Antibody-Mediated Neutralization of SARS-CoV-2 Sublineages KP.3.1.1 and XEC" Vaccines 13, no. 4: 385.
https://doi.org/10.3390/vaccines13040385
APA Style
Arora, P., Kempf, A., Nehlmeier, I., Schulz, S. R., Jäck, H.-M., Hoffmann, M., & Pöhlmann, S.
(2025). Entry Efficiency, Protease Dependence, and Antibody-Mediated Neutralization of SARS-CoV-2 Sublineages KP.3.1.1 and XEC. Vaccines, 13(4), 385.
https://doi.org/10.3390/vaccines13040385